ArticleJournal of community genetics2026
Readiness for precision medicine: pharmacogenomic literacy among adults surveyed in the United Arab Emirates: a cross-sectional study.
Article in Journal of community genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPharmacogenomics is increasingly being incorporated into precision medicine to support safer and more effective drug therapy. As the clinical use of pharmacogenomic testing expands, public understanding of its purpose and limitations becomes increasingly important. However, information on pharmacogenomic literacy among the general population in the United Arab Emirates (UAE) is scarce.
objectiveThis study aimed to assess pharmacogenomic literacy among adults in the UAE using the Minnesota Assessment of Pharmacogenomic Literacy (MAPL) and to examine sociodemographic and clinical factors associated with pharmacogenomic literacy.
methodsA cross-sectional online survey was conducted between March and May 2026 among adults living in the UAE. Pharmacogenomic literacy was measured using the validated 15-item MAPL. Scores were classified as low, moderate, or high according to Bloom's cut-off criteria. Descriptive statistics summarized participant characteristics and MAPL responses. Ordinal logistic regression was used to identify factors associated with pharmacogenomic literacy. Associations were reported as odds ratios (ORs) with 95% confidence intervals (CIs).
resultsA total of 626 individuals participated. The mean MAPL score was 8.1 (95% CI 7.9-8.2). Overall, 59.4% of participants had low pharmacogenomic literacy, 36.6% had moderate literacy, and 4.0% had high literacy. Participants generally showed good knowledge of basic genetic concepts, but important misconceptions were identified regarding the clinical role of pharmacogenomic testing. More than 60% incorrectly believed that pharmacogenomic testing could identify the best medication, predict responses to all medicines, or establish a medical diagnosis. Previous experience with genetic testing was associated with higher pharmacogenomic literacy (OR = 2.43, 95% CI 2.09-2.83; p < 0.001). Participants aged 35-44 years had slightly lower odds of higher literacy than those aged 45 years or older (OR = 0.91, 95% CI 0.82-1.00; p < 0.05). No significant associations were observed for sex and employment status.
conclusionsPharmacogenomic literacy among adults in the UAE was limited despite a reasonable understanding of basic genetic principles. The largest knowledge gaps concerned the clinical applications and limitations of pharmacogenomic testing. Previous genetic testing experience was associated with better literacy. These findings support accessible educational initiatives and patient-centered communication to promote informed use of pharmacogenomics as precision medicine becomes more widely implemented.
Indexed as
Identifiers
42911461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.